Feature

Global Ebola vaccine stockpile established


 

The International Coordinating Group (ICG) on Vaccine Provision announced the establishment of a global Ebola vaccine stockpile initiative.

The ICG, which was established in 1997, is made up of the World Health Organization, the United Nations Children’s Fund, the International Federation of Red Cross and Red Crescent Societies, and Médecins Sans Frontières.

The stockpile was created in order to make the single-dose Ebola vaccine (rVSVG-ZEBOV-GP, live; trade name Everbo) rapidly available at the start of the next Ebola outbreak anywhere in the world. The vaccine was developed and is marketed by Merck Sharp & Dohme, with financial support from the United States.

The stockpile, which is maintained in Switzerland and managed by UNICEF, is designed to be readily deployed to other countries whenever there is an outbreak. The ICG will be the decision-making body for the vaccine’s allocation and release, as is also the case with previously created stockpiles of cholera, meningitis, and yellow fever vaccines.

“The decision to allocate the vaccine will be made within 48 hours of receiving a request from a country; vaccines will be made available together with ultra-cold chain packaging by the manufacturer for shipment to countries within 48 hours of the decision. The targeted overall delivery time from the stockpile to countries is 7 days,” according to the WHO press release.

Currently 6,890 doses are available for outbreak response, with further quantities to be delivered into the stockpile throughout 2021 and beyond. Initial use of the vaccine will be directed to health care and frontline workers. It is expected that it will take 2-3 years to reach the Strategic Advisory Group of Experts on Immunization–recommended level of 500,000 doses for the stockpile of Ebola vaccines.

Recommended Reading

CDC panel recommends Pfizer’s COVID-19 vaccine for people 16 and over
Federal Practitioner
Understanding messenger RNA and other SARS-CoV-2 vaccines
Federal Practitioner
FDA gives guidance on allergy, pregnancy concerns for Pfizer COVID vaccine
Federal Practitioner
Moderna COVID-19 vaccine wins decisive recommendation from FDA panel
Federal Practitioner
FDA grants emergency use for Moderna COVID-19 vaccine
Federal Practitioner
Second COVID-19 vaccine ready for use, CDC panel says
Federal Practitioner
CDC identifies next priority groups for COVID-19 vaccine
Federal Practitioner
CDC issues COVID-19 vaccine guidance for underlying conditions
Federal Practitioner
Trust in a Vial
Federal Practitioner
Risk of HPV-related oropharyngeal cancer linked to number of oral sex partners
Federal Practitioner